IPCALAB vs KOPRAN: Stock Comparison
IPCA LABORATORIES is the larger company by market capitalisation. IPCA LABORATORIES shows a higher ROE, faster revenue growth and lower leverage, while KOPRAN shows a lower P/E and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
IPCALAB leads 9; KOPRAN leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | IPCALAB | KOPRAN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | IPCALAB | KOPRAN |
|---|---|---|
| Live Price | ₹1,965.3 | ₹232.54 |
| Day Change | 0.47% | 0.13% |
| Volume | 80,401 | 6.61 L |
| 52-Week High | ₹2,001.5 | ₹239.6 |
| 52-Week Low | ₹1,251.6 | ₹107 |
| Distance from 52W High | -1.81% | -2.95% |
Valuation
| Metric | IPCALAB | KOPRAN |
|---|---|---|
| Market Cap | ₹49,853 Cr | ₹1,120 Cr |
| P/E Ratio | 37.87x | 37.34x |
| P/B Ratio | 6.15x | 1.76x |
| EPS | ₹14.71 | ₹1.39 |
| Book Value | ₹375.4 | ₹109.82 |
| Dividend Yield | 0.31% | 2.76% |
Growth
| Metric | IPCALAB | KOPRAN |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.2% | -3.66% |
| EPS Growth (TTM YoY) | 341.6% | -71.88% |
| Qtr Sales Growth | -23.99% | -59.25% |
| Qtr Profit Growth | -12.02% | 0.33% |
Profitability & Leverage
| Metric | IPCALAB | KOPRAN |
|---|---|---|
| ROE | 14.19% | 4.85% |
| ROCE | 14.74% | 4.89% |
| Net Margin | 11.83% | 3.78% |
| Operating Margin | 21.48% | 6.58% |
| Debt to Equity | 0.03x | 0.29x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | IPCALAB | KOPRAN |
|---|---|---|
| Promoter Holding | 44.72% | 44.42% |
| FII Holding | 10.73%▲ 0.1 pp | 0.51%▼ 0.06 pp |
| DII Holding | 37.37%▼ 0.08 pp | 0% |
| Public Holding | 7.18%▼ 0.02 pp | 55.06%▲ 0.06 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA LABORATORIES and KOPRAN.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.